15/01/2026 11:56
|
Medical, Health & Aged Care
* Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030
* The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki,...